Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis.

ABSTRACT:

Background

Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-lasting effect. Even Ipilimumab, in combination with nivolumab, has demonstrated a significant clinical benefit in multiple tumor types. However, no trial has been designed with the primary endpoint to compare the efficacy of nivolumab plus ipilimumab combined, compared to nivolumab alone. Hence, the added value of ipilimumab in the combination has not clearly been established yet. The aim of this study was to demonstrate the superiority of the combination strategy compared to the single agent therapy.

Materials and methods

We performed a meta-analysis of Phase

SUBMITTER: Marchetti P 

PROVIDER: S-EPMC7688006 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature